Home page > EU Treaty Reform | Health at the Heart of the New Treaty | Chemicals and Pesticides | Health Intergroup | The European Convention | Inter-Governmental Conference (IGC) | Europe and Health | European Institutions

EU Institutions

What’s going on at the European Institutions, plus EU Programmmes, Policies, Legislation and Governance. Also covers European Food Safety Authority.

Please find all related articles below.

European Commission revised Investor Arbitration proposal still shows bias and lack of transparency

Brussels, 12 November 2015. Public health groups, including EPHA, EHN and EASL [1] consider that the proposed changes to investor arbitration in TTIP are insufficient to stop companies attacking governments on public health laws, such as those for plain tobacco packaging or transparency of clinical trials. The European Commission (DG TRADE) has today published its revised proposal for an Investment Court System (ICS ) [2] which aims to replace the highly controversial investor-to-state (...)

New EU International Trade Strategy fails to guarantee health protection

The European Commission has published today its proposal for a new EU Strategy on Trade. The proposed new Strategy, which should set out the EU approach to new international trade deals, including with Asia, falls short of providing safeguards to ensure that European national health services will be protected from threats to public funding or that quality will not be put at risk. Public health campaigners including EPHA insist that trade agreements should not undermine either the quality (...)

EPHA joins Better Regulation Watchdog

EPHA has joined more than 50 civil society organisations to create the ‘Better Regulation Watchdog’ – a network to protect citizens’, workers’ and consumers’ rights and health. The network was launched on 18 May in Brussels, one day ahead of the expected announcement of the European Commission’s Better Regulation initiative presented by First Vice-President Frans Timmermans. OPEN LETTER from the Better Regulation Watchdog Network in response to (...)

Health-related commitments of European Commissioners for Health, Industry and Social Affairs

November 2014 - The new Commission under President Jean-Claude Juncker officially took office on 1st November. EPHA has closely monitored the evaluation process of the new College of Commissioners and collected the health relevant commitments the Commissioners for Health and Food Safety; Internal Market, Industry, Entrepeneurship and SMEs; and Employment, Social Affairs, Skills and Labour Mobilty. Vytenis Andriukatis, Commissioner for Health and Food Safety (EPHA evaluation of his (...)

[Updated briefing notes] The impact of the economic crisis on public health

October 2014 - In 2012, EPHA published its first ‘facts and figures’ briefing on the impacts of the economic crisis on health. Two years later, the revised and updates briefing finds that the impacts of austerity politics and economic recession continue to threaten the health and wellbeing of Europeans. Trends in increased suicide rates, unemployment, social exclusion and unmet health needs prevail, most acutely in the newer member states and in those receiving financial (...)

[Report] Patients suffering from medicines shortages in all European countries

A new report on medicines shortages experienced in European healthcare systems reveals that over 86% of hospital pharmacists are experiencing difficulties in sourcing medicines with 66% reporting this as a daily or weekly problem. The top affected areas are medicines to fight infection, cancer drugs and anesthetics. Brussels, 17 November 2014 - The report by the European Association of Hospital Pharmacists (EAHP), surveyed the experiences of over 600 hospital pharmacists in 36 European (...)

Carlos Moedas » European Commissioner for Research, Science and Innovation

Carlos Moedas (age 44) studied engineering at Lisbon University, Portugal and an MBA at Harvard University, USA. He worked for Goldman Sachs and EuroHypo investment bank before returning to Portugal in 2004 to join a property consulting company, and established his own property investment company in 2008. He led negotiations for the Social Democratic Party (PSD) for Portugal’s 2011 State Budget. He was elected as an MP in the same year, and leading implementation of the (...)

[TTIP & Transparency Consultation] EPHA answers to the European Ombudsman Mrs Emily O’Reilly

Brussels, 30 October 2014 - On 29 July 2014, the European Ombudsman opened an own-initiative inquiry towards the European Commission concerning transparency and public participation in relation to the TTIP negotiations (OI/10/2014/RA). The present public consultation concerns that inquiry. The outcome of the TTIP negotiations could have a significant impact on the lives of citizens. The aim of the Ombudsman’s inquiry is to help ensure that the public can follow the progress of these (...)

Consultation on Commission’s Stakeholder Consultation Guidelines

EPHA welcomes the Commission’s publication of comprehensive consultation guidelines. Smart regulation should mean fair and citizen-centred policy making that brings tangible benefits to the citizens of Europe and improves their quality of life. This involves greater use of evidence-based impact assessment and improving the consultation process. The aim of the guidelines should be to ensure transparency and representativeness. Publishing consultation responses, as well as explanations (...)

[Joint press release] The European Health Community welcomes President-elect Juncker’s decision to ensure the security of all Europeans by regulating health for the public good

October 22th 2014, Brussels – The NGO signatories of this statement wholeheartedly welcome the announcement of the reversal of the decision by President-elect Jean-Claude Juncker to move the competence for pharmaceutical and medical devices to the enterprise directorate (1). Following negotiations within the European Parliament and concerns expressed by a number of member states, President-elect Juncker stated today that the "responsibility for medicines and pharmaceutical products (...)